Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis-Reference-Cited by-同舟云学术

Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis

Published:2006-02 Issue:2 Volume:44 Page:595-597
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Marty Francisco M.¹²³,Yeh Wendy W.¹³,Wennersten Christine B.⁴,Venkataraman Lata⁴,Albano Esperanza¹,Alyea Edwin P.⁵²³,Gold Howard S.⁴³,Baden Lindsey R.¹²³,Pillai Satish K.⁴³

Affiliation:

1. Division of Infectious Diseases

2. Dana-Farber Cancer Institute

3. Harvard Medical School, Boston, Massachusetts

4. Division of Infectious Diseases, Beth Israel Deaconess Medical Center

5. Division of Medical Oncology, Brigham & Women's Hospital

Abstract

ABSTRACT The emergence of a clinically daptomycin-resistant Staphylococcus aureus isolate occurred during treatment of methicillin-resistant S. aureus bacteremia and probable vertebral osteomyelitis. The breakthrough isolate was indistinguishable from pretreatment daptomycin-susceptible isolates by pulsed-field gel electrophoresis. Daptomycin nonsusceptibility was confirmed by MIC and time-kill curve analyses.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.44.2.595-597.2006

Reference17 articles.

1. Arbeit, R. D., D. Maki, F. P. Tally, E. Campanaro, and B. I. Eisenstein. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis.38:1673-1681.

2. Carpenter, C. F., and H. F. Chambers. 2004. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis.38:994-1000.

3. Center for Drug Evaluation and Research Food and Drug Administration. 15December 2003 posting date. NDA 21-572 Cubicin TM (daptomycin for injection). [Online.] http://www.fda.gov/cder/foi/nda/2003/21-572_Cubicin_Microbr_P2.pdf . Accessed 12 June 2005.

4. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement M100-S15. Clinical and Laboratory Standards Institute Wayne Pa.

5. Cubist Pharmaceuticals Inc. 2003 posting date. Cubicin TM (daptomycin for Injection) prescriber information. [Online.] http://www.cubicin.com/documents/cubicin_large_pi.pdf . Accessed 12 June 2005.

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asymmetric total synthesis of polycyclic xanthenes and discovery of a WalK activator active against MRSA;Nature Communications;2024-07-13

2. Anti-Staphy Peptides Rationally Designed from Cry10Aa Bacterial Protein;ACS Omega;2024-06-19

3. Glycyrrhizic Acid Nanoparticles Subside the Activity of Methicillin-Resistant Staphylococcus aureus by Suppressing PBP2a;Pharmaceuticals;2024-05-06

4. Systemic application of bone-targeting peptidoglycan hydrolases as a novel treatment approach for staphylococcal bone infection;mBio;2023-10-31

5. Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia;Journal of the Pediatric Infectious Diseases Society;2023-05-01